Pierre Pradat1, Pascal Pugliese2, Isabelle Poizot-Martin3, Marc-Antoine Valantin4, Lise Cuzin5, Jacques Reynes6, Eric Billaud7, Thomas Huleux8, Firouze Bani-Sadr9, David Rey10, Anne Frésard11, Christine Jacomet12, Claudine Duvivier13, Antoine Cheret14, Laurent Hustache-Mathieu15, Bruno Hoen16, André Cabié17, Laurent Cotte18. 1. Center for Clinical Research, Department of Hepatology, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France. Electronic address: pierre.pradat@univ-lyon1.fr. 2. Department of Infectious Diseases, Centre Hospitalier Universitaire de Nice, Hôpital l'Archet, Nice, France. 3. Immuno-hematology Clinic, Assistance Publique - Hôpitaux de Marseille, Hôpital Sainte-Marguerite, Marseille, France; Aix-Marseille University, Inserm U912 (SESSTIM), Marseille, France. 4. Department of Infectious Diseases, Assistance Publique - Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France; Sorbonne Universités, UPMC Université Paris 06, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France. 5. CHU Toulouse, COREVIH, Toulouse, France; Université de Toulouse III, Toulouse, France; INSERM, UMR, 1027, Toulouse, France. 6. Department of Infectious Diseases, UMI 233 INSERM U1175, CHU de Montpellier, Montpellier, France. 7. Department of Infectious Diseases, Hotel Dieu Hospital, Nantes, France. 8. Department of Infectious Diseases and Travel Diseases, Centre Hospitalier Gustave-Dron, Tourcoing, France. 9. Department of Internal Medicine, Infectious Diseases and Clinical Immunology, Hôpital Robert Debré, CHU, Reims, France; Université de Reims Champagne-Ardenne, Faculté de médecine, EA-4684/SFR CAP-SANTE, Reims, France. 10. HIV Infection Care Centre, Hôpitaux Universitaires, Strasbourg, France. 11. Department of Infectious Diseases, CHU, Saint-Etienne, France. 12. Department of Infectious Diseases, CHU Clermont-Ferrand, Clermont-Ferrand, France. 13. Department of Infectious Diseases, Centre d'Infectiologie Necker-Pasteur, IHU Imagine, Assistance Publique - Hôpitaux de Paris, Hôpital Necker-Enfants Malades, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France. 14. Department of Internal Medicine, CHU, Bicètre, France; Université Paris Descartes, Sorbonne Paris Cité, EA7327, Paris, France. 15. Department of Infectious Diseases, CHRU de Besançon, Besançon, France. 16. Faculté de Médecine Hyacinthe Bastaraud, Université des Antilles, and Service de Maladies Infectieuses et Tropicales, Dermatologie et Médecine Interne, and Inserm CIC 1424, Centre Hospitalier Universitaire de Pointe-à-Pitre, Pointe-à-Pitre, France. 17. Department of Infectious Diseases, CHU de Martinique, Fort-de-France, France; Université des Antilles EA4537 and INSERM CIC1424, Fort-de-France, France. 18. Department of Infectious Diseases, Croix-Rousse Hospital, Hospices Civils de Lyon, Lyon, France; INSERM U1052, Lyon, France. Electronic address: laurent.cotte@chu-lyon.fr.
Abstract
OBJECTIVES: Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfected patients. METHODS: All HIV-HCV patients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection. RESULTS: Among 32,945 HIV-infected patients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR. CONCLUSIONS: HCV treatment dramatically increased in HIV-HCV patients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIV patients will drastically decrease in the forthcoming years.
OBJECTIVES: Direct-Acting Antivirals (DAAs) opened a new era in HCV treatment. We report the impact of HCV treatment in French HIV-HCV coinfectedpatients. METHODS: All HIV-HCVpatients from the Dat'AIDS cohort followed between 2012 and 2015 were included. HCV status was defined yearly as naive, spontaneous cure, sustained virological response (SVR12), failure or reinfection. RESULTS: Among 32,945 HIV-infectedpatients, 15.2% were positive for anti-HCV antibodies. From 2012 to 2015, HCV incidence rate increased from 0.35%PY to 0.69%PY in MSM, while median incidence was 0.08%PY in other patients. Median reinfection rate was 2.56%PY in MSM and 0.22%PY in other patients. HCV treatment initiation rate rose from 8.2% in 2012 to 29.6% (48.0% in pre-treated patients vs 22.6% in naïve patients). SVR12 rate increased from 68.7% to 95.2%. By the end of 2015, 62.7% of the patients were cured either spontaneously or following SVR. CONCLUSIONS: HCV treatment dramatically increased in HIV-HCVpatients in France from 2012 to 2015 resulting in HCV cure in nearly two-thirds of the patients in this cohort. Combined with a declining HCV prevalence, the prevalence of active HCV infection among HIVpatients will drastically decrease in the forthcoming years.
Authors: Victor Virlogeux; Fabien Zoulim; Pascal Pugliese; Isabelle Poizot-Martin; Marc-Antoine Valantin; Lise Cuzin; Jacques Reynes; Eric Billaud; Thomas Huleux; Firouze Bani-Sadr; David Rey; Anne Frésard; Christine Jacomet; Claudine Duvivier; Antoine Cheret; Laurent Hustache-Mathieu; Bruno Hoen; André Cabié; Laurent Cotte Journal: BMC Med Date: 2017-12-18 Impact factor: 8.775
Authors: Lize Cuypers; Ana Belén Pérez; Natalia Chueca; Teresa Aldamiz-Echevarría; Juan Carlos Alados; Ana María Martínez-Sapiña; Dolores Merino; Juan Antonio Pineda; Francisco Téllez; Nuria Espinosa; Javier Salméron; Antonio Rivero-Juarez; María Jesús Vivancos; Víctor Hontañón; Anne-Mieke Vandamme; Féderico García Journal: PLoS One Date: 2018-07-25 Impact factor: 3.240